{"id":"131i","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypothyroidism"},{"rate":null,"effect":"Radiation thyroiditis"},{"rate":null,"effect":"Salivary gland dysfunction"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"131I is taken up selectively by thyroid follicular cells through the sodium-iodide symporter, concentrating in the thyroid gland where it delivers targeted radiation to ablate normal thyroid tissue or thyroid cancer. The beta radiation causes direct cellular damage and cell death in iodine-avid tissues. This mechanism allows treatment of hyperthyroidism and radioiodine-avid thyroid cancers with relatively selective targeting to the thyroid.","oneSentence":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid tissue and thyroid cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:24:50.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thyroid cancer (radioiodine-avid differentiated thyroid cancer)"},{"name":"Hyperthyroidism"}]},"trialDetails":[{"nctId":"NCT06465017","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer","status":"TERMINATED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-01-04","conditions":"Tumor, Solid Tumor, Thyroid Cancer","enrollment":149},{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","enrollment":40},{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT07100730","phase":"PHASE3","title":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-11-02","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma (GBM)","enrollment":50},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05599139","phase":"NA","title":"Iodine Uptake After a Low Iodine Diet","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2023-02-22","conditions":"Differentiated Thyroid Cancer","enrollment":25},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT05450744","phase":"PHASE1","title":"131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2023-04-01","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme","enrollment":12},{"nctId":"NCT07353333","phase":"NA","title":"Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"HCC, SPECT-CT","enrollment":6},{"nctId":"NCT03484884","phase":"","title":"A Study of Optical Imaging With Light From Radiotracers in Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-03-20","conditions":"Thyroid Cancer","enrollment":102},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":"Neuroblastoma","enrollment":118},{"nctId":"NCT06458036","phase":"PHASE2","title":"Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2024-07-29","conditions":"Differentiated Thyroid Cancer, Pediatric Cancer, Cancer","enrollment":13},{"nctId":"NCT05783323","phase":"PHASE2","title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2024-02-14","conditions":"Differentiated Thyroid Cancer, Pediatric Cancer, Cancer","enrollment":13},{"nctId":"NCT03939689","phase":"PHASE2","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","status":"COMPLETED","sponsor":"Progenics Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm","enrollment":120},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT03165292","phase":"PHASE2","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-10-01","conditions":"Very High Risk Neuroblastoma","enrollment":34},{"nctId":"NCT06371339","phase":"NA","title":"Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2024-04-25","conditions":"Hyperthyroidism","enrollment":22},{"nctId":"NCT05064306","phase":"","title":"131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults","status":"NO_LONGER_AVAILABLE","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"","conditions":"Central Nervous System/Leptomeningeal Neoplasms","enrollment":""},{"nctId":"NCT01370330","phase":"","title":"131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol","status":"AVAILABLE","sponsor":"Kieuhoa Vo","startDate":"","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT04022213","phase":"PHASE2","title":"A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-15","conditions":"Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma","enrollment":31},{"nctId":"NCT03215095","phase":"EARLY_PHASE1","title":"RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-07-10","conditions":"Thyroid Cancer","enrollment":11},{"nctId":"NCT02145143","phase":"EARLY_PHASE1","title":"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-05-20","conditions":"Thyroid Carcinoma","enrollment":12},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT06768905","phase":"PHASE1, PHASE2","title":"Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-04-25","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT03332667","phase":"PHASE1","title":"MIBG With Dinutuximab +/- Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2018-09-12","conditions":"Neuroblastoma","enrollment":45},{"nctId":"NCT06000787","phase":"NA","title":"MCT for the Harvard/UCSF ROBIN Center","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-09-19","conditions":"Glioma, Childhood Brainstem, Neuroblastoma","enrollment":47},{"nctId":"NCT03784625","phase":"EARLY_PHASE1","title":"Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2019-10-18","conditions":"Melanoma","enrollment":10},{"nctId":"NCT03649438","phase":"","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"University of Texas Southwestern Medical Center","startDate":"","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT06669481","phase":"","title":"Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-01","conditions":"Pheochromocytoma, Paraganglioma","enrollment":159},{"nctId":"NCT03015844","phase":"","title":"A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","status":"AVAILABLE","sponsor":"Northwell Health","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":""},{"nctId":"NCT06431620","phase":"NA","title":"Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-30","conditions":"Recombinant Human Thyroid Stimulating Hormone","enrollment":15},{"nctId":"NCT06405217","phase":"NA","title":"Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-04-20","conditions":"DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications","enrollment":30},{"nctId":"NCT05982626","phase":"NA","title":"Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-05-15","conditions":"HER2-positive Breast Cancer","enrollment":10},{"nctId":"NCT04971473","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-09-10","conditions":"Differentiated Thyroid Cancer","enrollment":201},{"nctId":"NCT06259422","phase":"NA","title":"Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-06-01","conditions":"Kidney Function Issue, Diagnosis, Chronic Kidney Diseases","enrollment":208},{"nctId":"NCT03275402","phase":"PHASE2, PHASE3","title":"131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases","status":"TERMINATED","sponsor":"Y-mAbs Therapeutics","startDate":"2018-12-11","conditions":"Neuroblastoma, CNS Metastases, Leptomeningeal Metastases","enrollment":52},{"nctId":"NCT06201741","phase":"NA","title":"A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2023-12-27","conditions":"Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer","enrollment":10},{"nctId":"NCT00089245","phase":"PHASE1","title":"Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer","status":"TERMINATED","sponsor":"Y-mAbs Therapeutics","startDate":"2004-02-05","conditions":"Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma","enrollment":177},{"nctId":"NCT00509353","phase":"PHASE1","title":"N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2007-01","conditions":"Neuroblastoma","enrollment":26},{"nctId":"NCT05182931","phase":"PHASE2","title":"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","status":"UNKNOWN","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2022-07-14","conditions":"Thyroid Cancer","enrollment":80},{"nctId":"NCT04447183","phase":"PHASE2","title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-11-23","conditions":"Differentiated Thyroid Cancer","enrollment":120},{"nctId":"NCT04964284","phase":"PHASE3","title":"Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-10-06","conditions":"Differentiated Thyroid Cancer","enrollment":328},{"nctId":"NCT00574509","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1996-03-04","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT00003102","phase":"PHASE1, PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"1998-11-17","conditions":"Kidney Cancer","enrollment":15},{"nctId":"NCT04660396","phase":"","title":"Monitoring Outpatient Blood VolumE in Heart Failure","status":"COMPLETED","sponsor":"Daxor Corporation","startDate":"2021-09-16","conditions":"Heart Failure","enrollment":15},{"nctId":"NCT01838187","phase":"","title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","status":"NO_LONGER_AVAILABLE","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT03044977","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2017-05-07","conditions":"Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting","enrollment":20},{"nctId":"NCT05989425","phase":"PHASE2","title":"Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-04","conditions":"Differentiated Thyroid Cancer","enrollment":32},{"nctId":"NCT05063357","phase":"PHASE1","title":"131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma","status":"WITHDRAWN","sponsor":"Y-mAbs Therapeutics","startDate":"2022-03","conditions":"DIPG","enrollment":""},{"nctId":"NCT01321554","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-03-17","conditions":"Thyroid Cancer","enrollment":392},{"nctId":"NCT01837745","phase":"PHASE3","title":"Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2013-05-13","conditions":"Low Risk Differentiated Thyroid Cancer","enrollment":776},{"nctId":"NCT03849105","phase":"PHASE1, PHASE2","title":"131I-IPA and Concurrent XRT in Recurrent GBM","status":"COMPLETED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2019-04-09","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT04085991","phase":"PHASE2","title":"Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-07-31","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostatic Neoplasms","enrollment":11},{"nctId":"NCT00253435","phase":"PHASE2","title":"N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2005-09","conditions":"Neuroblastoma","enrollment":50},{"nctId":"NCT04922801","phase":"","title":"Optimising Molecular Radionuclide Therapy","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-12-09","conditions":"Neuroendocrine Tumors, Hyperthyroidism, Thyroid Cancer","enrollment":50},{"nctId":"NCT01590680","phase":"","title":"Expanded Access Protocol Using 131I-MIBG","status":"AVAILABLE","sponsor":"Jubilant DraxImage Inc.","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT02278315","phase":"PHASE1","title":"Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Cellectar Biosciences, Inc.","startDate":"2015-02","conditions":"Multiple Myeloma","enrollment":31},{"nctId":"NCT03561259","phase":"PHASE2","title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","status":"UNKNOWN","sponsor":"Jubilant DraxImage Inc.","startDate":"2019-10-21","conditions":"Neuroblastoma, Neuroectodermal Tumors, Neoplasms","enrollment":60},{"nctId":"NCT02773667","phase":"","title":"Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2016-01","conditions":"Thyroid Carcinoma","enrollment":83},{"nctId":"NCT05468554","phase":"PHASE3","title":"Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2022-11-01","conditions":"Thyroid Cancer","enrollment":160},{"nctId":"NCT00291486","phase":"PHASE1","title":"Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2003-10","conditions":"Colorectal Neoplasms","enrollment":19},{"nctId":"NCT03427320","phase":"PHASE1, PHASE2","title":"Imaging of Advanced Tumours Using [131]I-IAZA","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2018-12","conditions":"Locally Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":""},{"nctId":"NCT02035137","phase":"PHASE2","title":"131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-07","conditions":"Neuroblastoma","enrollment":114},{"nctId":"NCT02731352","phase":"PHASE2","title":"Study of Apatinib in Patients With Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2016-03-11","conditions":"Thyroid Cancer","enrollment":20},{"nctId":"NCT02702388","phase":"PHASE2","title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-06-08","conditions":"Thyroid Cancer","enrollment":241},{"nctId":"NCT04916262","phase":"","title":"Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-06-20","conditions":"Differentiated Thyroid Carcinoma, TCM Syndrome Type","enrollment":160},{"nctId":"NCT03923257","phase":"PHASE1, PHASE2","title":"Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2020-08-04","conditions":"Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT01583842","phase":"EARLY_PHASE1","title":"124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study","status":"TERMINATED","sponsor":"Miguel Pampaloni","startDate":"2013-04-09","conditions":"Neuroblastoma","enrollment":10},{"nctId":"NCT01377532","phase":"","title":"Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma","status":"APPROVED_FOR_MARKETING","sponsor":"University of California, San Francisco","startDate":"","conditions":"Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT00860171","phase":"PHASE1","title":"Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma","enrollment":16},{"nctId":"NCT04180007","phase":"PHASE2","title":"Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-04-10","conditions":"Thyroid, Metastasis, Apatinib","enrollment":10},{"nctId":"NCT01843062","phase":"PHASE3","title":"Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-08-27","conditions":"Differentiated Thyroid Cancer","enrollment":233},{"nctId":"NCT02683083","phase":"PHASE1","title":"Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients","status":"COMPLETED","sponsor":"Precirix","startDate":"2016-10","conditions":"Healthy Volunteers, Breast Cancer","enrollment":9},{"nctId":"NCT02586337","phase":"PHASE2, PHASE3","title":"Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2015-07","conditions":"Differentiated Thyroid Cancer","enrollment":113},{"nctId":"NCT01313936","phase":"PHASE1","title":"High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03","conditions":"Neuroblastoma","enrollment":32},{"nctId":"NCT03030885","phase":"PHASE1","title":"Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":10},{"nctId":"NCT02870569","phase":"PHASE2","title":"Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2016-09","conditions":"Differentiated Thyroid Cancer","enrollment":48},{"nctId":"NCT00085293","phase":"PHASE2","title":"Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":"Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer","enrollment":12},{"nctId":"NCT01833650","phase":"NA","title":"The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer","status":"COMPLETED","sponsor":"Cyprus University of Technology","startDate":"2013-05","conditions":"Thyroid Cancer","enrollment":120},{"nctId":"NCT01413503","phase":"PHASE2","title":"A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1991-05","conditions":"Pheochromocytoma, Paraganglioma","enrollment":50},{"nctId":"NCT03061656","phase":"PHASE2","title":"Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"High Risk Neuroblastoma","enrollment":40},{"nctId":"NCT02602067","phase":"PHASE1","title":"131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients","status":"TERMINATED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2015-11","conditions":"Breast Neoplasm, Head and Neck Neoplasm, Skin Neoplasm","enrollment":2},{"nctId":"NCT00416312","phase":"","title":"Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-07","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT02988648","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2016-12","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00777114","phase":"PHASE1","title":"Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-04-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT03574051","phase":"EARLY_PHASE1","title":"the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-05-01","conditions":"Microbiota","enrollment":30},{"nctId":"NCT01664936","phase":"","title":"Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-08-08","conditions":"Head and Neck Cancers","enrollment":27},{"nctId":"NCT00004874","phase":"PHASE3","title":"Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"1998-11","conditions":"Lymphoma","enrollment":31},{"nctId":"NCT01269749","phase":"PHASE2","title":"Radioactive Iodide Therapy for Pediatric Graves' Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-10","conditions":"Graves' Disease","enrollment":19},{"nctId":"NCT00476047","phase":"PHASE2","title":"Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-02","conditions":"Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia","enrollment":16},{"nctId":"NCT00970359","phase":"NA","title":"Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09","conditions":"Thyroid Cancer","enrollment":24},{"nctId":"NCT00434629","phase":"PHASE1","title":"Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-02","conditions":"B-cell Lymphoma, Non-Hodgkin's Lymphoma","enrollment":16},{"nctId":"NCT01099228","phase":"NA","title":"Combination Targeted Radiotherapy in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"David Bushnell","startDate":"2006-09","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT01360177","phase":"NA","title":"Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2010-07","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT01403324","phase":"NA","title":"Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-09","conditions":"Thyroid Cancer, Metastases","enrollment":4},{"nctId":"NCT00819650","phase":"PHASE2","title":"A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2008-12","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT02724267","phase":"NA","title":"Targeted Internal Radiation Therapy in Advanced HCC Patients.","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2012-11","conditions":"Internal Radiation, Advanced Hepatocellular Carcinoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12883,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"131I","genericName":"131I","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid tissue and thyroid cancer cells. Used for Thyroid cancer (radioiodine-avid differentiated thyroid cancer), Hyperthyroidism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}